论文部分内容阅读
卡托普利先经衍生化形成具有紫外吸收的衍生物,然后用6％的高氯酸去蛋白,取上清液直接进样。以μBoundapak C_(18)(37～50μm)作为预处理柱(5cm×O.5cm,ID),对样品进行自动浓缩净化处理,预处理流动相为0.2％醋酸溶液。分析柱(15cm×O.5cm,ID)固定相为YWG-C_(13),10μm,流动相为乙晴-水-醋酸(35:65:0.4)。UV 260nm检测。血浆和尿样测定的线性范围分别为20～1000ng/ml和10～200μg/ml,血浆中最低检测浓度约为10ng/ml。方法的平均回收率分别为103.2％(血浆)和99.5％(尿样),日内及日间变异均小于10％。
Captopril is first derivatized to form a derivative with UV absorbance, then deproteinized with 6% perchloric acid, and the supernatant is injected directly. The sample was automatically concentrated and purified with μBoundapak C_ (18) (37 ~ 50μm) as pretreatment column (5cm × 0.5cm, ID). The mobile phase was 0.2% acetic acid solution. The analytical column (15 cm × 0.5 cm, ID) was YWG-C 13 with a mobile phase of acetonitrile-water-acetic acid (35:65:40). UV 260nm detection. The linear range of plasma and urine samples was 20 to 1000 ng / ml and 10 to 200 μg / ml, respectively, and the lowest detectable concentration in plasma was about 10 ng / ml. The average recoveries for the method were 103.2% (plasma) and 99.5% (urine) respectively, with intra-day and inter-day variability of less than 10%.